The PAX5alt subtype therefore accounted for 7.1% of our whole B-ALL cohort and 29.1% of the B-other group, while the one patient with PAX5 P80R represented 1.0% of the whole cohort and 4.2% of the B-other group. The gene discussed is PAX5; the disease is acute lymphoblastic leukemia.